Clinical-stage biotechnology company developing CAR-TEAM, an autologous T-cell immunotherapy platform that combines CAR-T cells with secreted bispecific T-cell-engaging antibody molecules to target difficult-to-treat solid tumors
Clinical-stage biotechnology company developing CAR-TEAM, an autologous T-cell immunotherapy platform that combines CAR-T cells with secreted bispecific T-cell-engaging antibody molecules to target difficult-to-treat solid tumors. Its lead program, ALTX-100, is in clinical development for glioblastoma and is delivered intraventricularly.